0001564590-22-019671 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2022	May 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	SYBX
Entity Registrant Name	SYNLOGIC, INC.
Security Exchange Name	NASDAQ
Entity Central Index Key	0001527599
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Entity Common Stock, Shares Outstanding		70,250,681
Entity Address, State or Province	MA
Entity File Number	001-37566
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1824804
Entity Address, Address Line One	301 Binney St.
Entity Address, Address Line Two	Suite 402
Entity Address, City or Town	Cambridge
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	401-9975
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,851	$ 16,438
Short-term marketable securities	99,667	112,150
Prepaid expenses and other current assets	3,900	4,721
Total current assets	124,418	133,309
Long-term marketable securities		8,041
Property and equipment, net	9,082	9,088
Right of use asset - operating lease	14,893	13,889
Restricted cash	1,097	1,097
Prepaid research and development, net of current portion	9,797	9,309
Other assets	22	3
Total assets	159,309	174,736
Current liabilities:
Accounts payable	2,409	1,944
Accrued expenses	2,668	4,402
Deferred revenue	314	531
Lease liability - operating lease	4,261	3,191
Finance lease obligations	12	12
Total current liabilities	9,664	10,080
Long-term liabilities:
Lease liability - operating lease, net of current portion	17,336	17,372
Finance lease obligations, net of current portion	15	18
Total long-term liabilities	17,351	17,390
Commitments and contingencies (Note 11)
Stockholders' equity
Common stock, $0.001 par value 250,000,000 shares authorized as of March 31, 2022 and December 31, 2021. 70,267,586 shares issued and outstanding as of March 31, 2022 and 69,698,844 shares issued and outstanding as of December 31, 2021.	70	70
Additional paid-in capital	439,138	438,113
Accumulated other comprehensive loss	(345)	(45)
Accumulated deficit	(306,569)	(290,872)
Total stockholders' equity	132,294	147,266
Total liabilities and stockholders' equity	$ 159,309	$ 174,736

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	250,000,000	250,000,000
Common stock, Issued	70,267,586	69,698,844
Common stock, outstanding	70,267,586	69,698,844

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 244
Operating expenses:
Research and development	11,738	$ 11,180
General and administrative	4,271	3,851
Total operating expenses	16,009	15,031
Loss from operations	(15,765)	(15,031)
Other income (expense):
Interest and investment income	67	60
Interest expense	(1)
Other income	2
Other income (expense), net	68	60
Net loss	$ (15,697)	$ (14,971)
Net loss per share - basic and diluted	$ (0.22)	$ (0.36)
Weighted-average common stock outstanding - basic and diluted	71,969,007	41,545,050
Comprehensive loss:
Net loss	$ (15,697)	$ (14,971)
Net unrealized (loss) gain on marketable securities	(300)	(9)
Comprehensive loss	$ (15,997)	$ (14,980)

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	At-the-market Offering	Common Stock $0.001 Par Value	Common Stock $0.001 Par Value At-the-market Offering	Additional Paid-in Capital	Additional Paid-in Capital At-the-market Offering	Accumulated Deficit	Accumulated Deficit
Balance at Dec. 31, 2020	$ 115,135		$ 38		$ 345,394		$ 14	$ (230,311)
Balance (in Shares) at Dec. 31, 2020			38,183,273
Proceeds from issuance of common stock, net of issuance costs		$ 8,050		$ 3		$ 8,047
Proceeds from issuance of common stock, net of issuance costs, Shares				2,447,211
Issuance of common stock under employee stock purchase plan	33				33
Issuance of common stock under employee stock purchase plan, Shares			19,061
Exercise of options, shares			216
Issuance of restricted stock, shares			242,454
Restricted stock awards withheld for payment of employees' withholding tax liability	(65)				(65)
Restricted stock awards withheld for payment of employees' withholding tax liability, Shares			(15,970)
Cancellation of restricted stock			(2,719)
Equity-based compensation expense	877				877
Unrealized gain (loss) on securities	(9)						(9)
Net loss	(14,971)							(14,971)
Balance at Mar. 31, 2021	109,050		$ 41		354,286		5	(245,282)
Balance (in Shares) at Mar. 31, 2021			40,873,526
Balance at Dec. 31, 2021	147,266		$ 70		438,113		(45)	(290,872)
Balance (in Shares) at Dec. 31, 2021			69,698,844
Issuance of common stock under employee stock purchase plan	83				83
Issuance of common stock under employee stock purchase plan, Shares			40,528
Exercise of options	52				52
Exercise of options, shares			30,622
Issuance of restricted stock, shares			507,260
Cancellation of restricted stock			(9,668)
Equity-based compensation expense	890				890
Unrealized gain (loss) on securities	(300)						(300)
Net loss	(15,697)							(15,697)
Balance at Mar. 31, 2022	$ 132,294		$ 70		$ 439,138		$ (345)	$ (306,569)
Balance (in Shares) at Mar. 31, 2022			70,267,586

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (15,697)	$ (14,971)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	601	626
Equity-based compensation expense	890	877
Accretion/amortization of investment securities	(11)	105
Change in carrying amount of operating lease right of use asset	769	462
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	821	(443)
Prepaid research and development, net of current portion	(488)	1,382
Accounts payable and accrued expenses	(1,387)	(1,408)
Deferred revenue	(217)
Operating lease liabilities	(739)	(606)
Other assets	(19)
Net cash used in operating activities	(15,477)	(13,976)
Cash flows from investing activities:
Purchases of marketable securities	(12,121)	(27,091)
Proceeds from maturity of marketable securities	32,356	25,996
Proceeds from redemption of marketable securities		1,270
Purchases of property and equipment	(477)	(21)
Net cash provided by investing activities	19,758	154
Cash flows from financing activities:
Payments on finance lease obligations	(3)	(1)
Proceeds from employee stock purchases and exercise of stock options	135	33
Payment of employee withholding taxes relating to restricted stock awards		(65)
Net cash provided by financing activities	132	8,019
Net increase (decrease) in cash, cash equivalents and restricted cash	4,413	(5,803)
Cash, cash equivalents and restricted cash at beginning of period	17,535	33,604
Cash, cash equivalents and restricted cash at end of period	21,948	27,801
Supplemental disclosure of non-cash investing activities:
Assets acquired under operating lease obligation	1,773
Property and equipment purchases included in accounts payable and accrued expenses	118	3
Supplemental disclosure of non-cash financing activities:
Issuance costs included in accounts payable and accrued expenses		2
Cash paid for interest	$ 1
At-the-market Offering
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		$ 8,052

Nature of Business

3 Months Ended

Mar. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Business

(1)	Nature of Business

Organization

Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or “the Company”), is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of Synthetic Biotics. Synthetic Biotics are generated from Synlogic’s proprietary platform, leveraging a reproducible, modular approach to the generation of novel drug candidates that perform or deliver critical therapeutic functions. Synthetic Biotics are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic’s goal is to discover, develop and ultimately commercialize Synthetic Biotics. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.

Risks and Uncertainties

At March 31, 2022, the Company had approximately $120.5 million in cash, cash equivalents, and short-term marketable securities, $1.1 million of restricted cash and an accumulated deficit of approximately $306.6 million. Since its inception through March 31, 2022, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, the collaborations with Roche and AbbVie, and cash received in the Merger (defined below). In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements.

As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or alliances.

COVID-19

While the Company is not aware of a material impact from the continuation of the COVID-19 pandemic through March 31, 2022, the full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations, and financial condition, including expenses and manufacturing, clinical trials, and research and development costs, depends on future developments that are highly uncertain at this time.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

(2)	Summary of Significant Accounting Policies

The significant accounting policies described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (SEC) on March 17, 2022 (the 2021 Annual Report), have had no material changes during the three months ended March 31, 2022.

Basis of Presentation

The accompanying consolidated financial statements and the related disclosures as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the Company’s 2021 and 2020 audited consolidated financial statements and notes included in the 2021 Annual Report. The consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial

statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three months ended March 31, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any other interim period or future year or period.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Recently Issued Accounting Pronouncements

New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

(3)	Fair Value of Financial Instruments

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2, Summary of Significant Accounting Policies, in the audited financial statements included in the 2021 Annual Report.

The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations. In addition, model processes were used to assess interest rate impact and develop prepayment scenarios. These models take into consideration relevant credit information, perceived market movements, sector news and economic events. The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.

At March 31, 2022 and December 31, 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at Reporting Date Using
	March 31,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2022		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	20,851	$	20,851	$	—	$	—
Commercial paper		88,100		—		88,100		—
Corporate debt securities		3,617		—		3,617		—
U.S. government agency securities and treasuries		7,950		7,950		—		—
Total	$	120,518	$	28,801	$	91,717	$	—

	Fair Value Measurements at Reporting Date Using
	December 31,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2021		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	16,437	$	16,437	$	—	$	—
Commercial paper		106,277		—		106,277		—
Corporate debt securities		5,873		—		5,873		—
U.S. government agency securities and treasuries		8,041		8,041		—		—
Total	$	136,628	$	24,478	$	112,150	$	—

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at March 31, 2022 and December 31, 2021 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at March 31, 2022 and December 31, 2021 approximate fair value as they bear interest at a rate approximating a market interest rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Available-for-Sale Investments

3 Months Ended

Mar. 31, 2022

Investments Debt And Equity Securities [Abstract]

Available-for-Sale Investments

(4)	Available-for-Sale Investments

The following tables summarize the available-for-sale securities held at March 31, 2022 and December 31, 2021 (in thousands):

March 31, 2022	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	88,342	$	—	$	(242	)	$	88,100
Corporate debt securities		3,620		—		(3	)		3,617
U.S. government agency securities and treasuries		8,050		—		(100	)		7,950
Total	$	100,012	$	—	$	(345	)	$	99,667

December 31, 2021	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	106,298	$	8	$	(29	)	$	106,277
Corporate debt securities		5,876		—		(3	)		5,873
U.S. government agency securities and treasuries		8,062		—		(21	)		8,041
Total	$	120,236	$	8	$	(53	)	$	120,191

The contractual maturity of all securities held at March 31, 2022 was twelve months or less. There were 28 and 20 investments in an unrealized loss position at March 31, 2022 and December 31, 2021, respectively, none of which had been in an unrealized loss position for more than twelve months. The aggregate fair value of the securities in an unrealized loss position at March 31, 2022 and December 31, 2021 was $99.7 million and $72.2 million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company did not hold any securities with an other-than-temporary impairment at March 31, 2022.

Gross realized gains and losses on the sales of investments have not been material to the Company’s consolidated statement of operations.

Property and Equipment, Net

3 Months Ended

Mar. 31, 2022

Property Plant And Equipment [Abstract]

Property and Equipment, Net

(5)	Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

	March 31,			December 31,
	2022			2021
Laboratory equipment	$	8,600		$	8,274
Computer and office equipment		795			756
Furniture and fixtures		500			500
Leasehold improvements		9,566			9,561
Construction in progress		848			623
		20,309			19,714
Less accumulated depreciation		(11,227	)		(10,626	)
Property and equipment, net	$	9,082		$	9,088

Accrued Expenses

3 Months Ended

Mar. 31, 2022

Payables And Accruals [Abstract]

Accrued Expenses

(6)	Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31,		December 31,
	2022		2021
Payroll related	$	1,546	$	3,495
Professional fees		398		298
Research and development		450		336
Other		274		273
Total accrued expenses	$	2,668	$	4,402

Stockholders' Equity

3 Months Ended

Mar. 31, 2022

Equity [Abstract]

Stockholders' Equity

(7)	Stockholders’ Equity

In June 2019, the Company issued to Ginkgo Bioworks, Inc. (Ginkgo) an aggregate of 6,340,771 shares of common stock at a purchase price per share of $9.00, and pre-funded warrants (the Pre-Funded Warrants) to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The net proceeds to the Company were approximately $79.9 million. None of the Pre-Funded Warrants have been exercised as of March 31, 2022. (See Note 9, Collaboration Agreements: Ginkgo Collaboration).

The Company had a previous sales agreement with Cowen and Company, LLC (Cowen) with respect to an at-the-market (ATM) offering program, which was entered into on October 13, 2017. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the three months ended March 31, 2021, 2,447,211 shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $8.1 million. There were no sales pursuant to the Cowen ATM subsequent to March 31, 2021.

In July 2021, the Company entered into a new sales agreement with Jefferies, LLC (Jefferies) with respect to an ATM, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having aggregate sales proceeds of up to $50.0 million. Jefferies is not required to sell any specific amount but acts as the Company’s sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. During the three months ended March 31, 2022, no shares of common stock were sold pursuant to the sales agreement with Jefferies.

The Company has reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan:

	March 31, 2022
Common stock issuable under pre-funded warrants		2,548,117
Options exercisable to purchase common stock		2,279,425
Employee Stock Purchase Plan		—
Total		4,827,542

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Equity-based Compensation

3 Months Ended

Mar. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-based Compensation

(8)	Equity‑based Compensation

On January 1, 2022, the number of shares of common stock available for issuance under the 2015 Equity Incentive Award Plan (the “2015 Plan”) and the 2015 Employee Stock Purchase Plan (“ESPP”) was increased by 3,484,942 shares and 696,988 shares, respectively, due to the annual evergreen provision to increase shares available under the 2015 Plan and the ESPP. As of March 31, 2022, there were an aggregate of 2,461,519 shares available for future grant under the 2017 Stock Incentive Plan (the 2017 Plan) and the 2015 Plan, and 1,341,301 shares available for future grant under the ESPP.

The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 (in thousands):

	Three Months Ended March 31,
	2022		2021
Research and development	$	375	$	415
General and administrative		515		462
	$	890	$	877

The following table summarizes equity‑based compensation expense by type of award for the three months ended March 31, 2022 and 2021 (in thousands):

	Three Months Ended March 31,
	2022		2021
Stock options	$	820	$	699
Restricted stock awards		53		172
Employee stock purchase plan		17		6
	$	890	$	877

During the three months ended March 31, 2022, the Company granted 2,342,899 stock options with a weighted average exercise price of $1.99. As of March 31, 2022, there was $7.5 million of unrecognized share-based compensation related to unvested stock option grants which is expected to be recognized over a weighted average period of 2.9 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.

During the three months ended March 31, 2022, the Company granted 507,260 restricted stock awards with a weighted average grant date fair value per share of $1.97. As of March 31, 2022, there was approximately $1.6 million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of 3.5 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.

For a full description of the Company’s equity plans, refer to Note 9, Equity-based Compensation and Equity Incentive Plans in the 2021 Annual Report.

Collaboration Agreements

3 Months Ended

Mar. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration Agreements

(9)	Collaboration Agreements

Roche Collaboration

In June 2021, the Company entered into a Pilot Collaboration and Option Agreement (the Roche Collaboration and Option Agreement) with F. Hoffmann-La Roche Ltd (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche). Under the terms of the Roche Collaboration and Option Agreement, the Company and Roche will seek to collaborate to research and pre-clinically develop Synthetic Biotics for addressing an undisclosed novel target for the treatment of inflammatory bowel disease.

The Company recognized $0.2 million for the three months ended March 31, 2022 as collaboration revenue in the Company’s consolidated statements of operations and comprehensive loss associated with the Roche Collaboration and Option Agreement. Deferred revenue from the collaboration amounted to $0.3 million as of March 31, 2022, all of which is included in current liabilities.

For a full description of the Roche Collaboration and Option Agreement, refer to Note 10, Collaboration Agreements in the 2021 Annual Report.

Ginkgo Collaboration

In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products (See Note 7). Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. The prepayment of foundry services is recorded in Prepaid expenses and other current assets and Prepaid research and development, net of current portion on the March 31, 2022 consolidated balance sheet. At March 31, 2022, the Company had remaining balances of $0.9 million and $9.8 million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.

Net Loss per Share

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Net Loss per Share

(10)	Net Loss per Share

Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock and outstanding stock options. In June 2019, the Company sold 6,340,771 shares of common stock and Pre-Funded Warrants to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering (see Note 10, Ginkgo Collaboration, in the audited financial statements included in the 2021 Annual Report). The shares of common stock into which the warrants may be exercised are considered outstanding for the purposes of computing net loss per share.

The Company’s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.

	As of March 31,
	2022		2021
Unvested restricted common stock awards		793,693		415,158
Outstanding options to purchase common stock		6,684,468		4,577,117
Potential shares issuable under the ESPP		—		—

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

(11)	Commitments and Contingencies

In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.

The Company’s commitments are described in the Company’s consolidated financial statements as of and for the year ended December 31, 2021 and the notes thereto included in the Annual Report on Form 10-K filed with the SEC on March 17, 2022. On January 21, 2022, the Company entered into two Statements of Work with Azzur Group, LLC (Azzur). Pursuant to the first of the SOWs (the Third SOW), the Company has agreed to pay Azzur $650,000 to renovate and upgrade the cleanroom space at Azzur for the Company’s expanded use. The second of the SOWs (the Fourth SOW) replaces the Second SOW that the Company entered into with Azzur on April 29, 2021. The Fourth SOW extends the term of the lease, for the period beginning January 2022 through March 2023 (the Third Term). The Fourth SOW contains an option to extend the lease by a period of three months. The Company determined

that it was more likely than not to exercise the option to extend the lease. The total estimated project cost during the Third Term, for access to, and use of, the renovated and upgraded cleanroom space at Azzur, and the personnel support and other services, is $3.1 million. The Third and Fourth SOWs resulted in an adjustment to the operating lease right-of-use asset and corresponding operating lease liabilities of $1.8 million. For a full description of the Azzur embedded lease, refer to Note 13, Leases in the 2021 Annual Report.

Related-Party Transactions

3 Months Ended

Mar. 31, 2022

Related-Party Transactions

(12)	Related-Party Transactions

In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of March 31, 2022, Ginkgo owns 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration, in the audited financial statements included in the 2021 Annual Report.

Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At March 31, 2022, the Company had remaining balances of $0.9 million and $9.8 million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the three months ended March 31, 2022, the Company used $0.5 million of the pre-paid research and development expenses.

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements and the related disclosures as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the Company’s 2021 and 2020 audited consolidated financial statements and notes included in the 2021 Annual Report. The consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three months ended March 31, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any other interim period or future year or period.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis

At March 31, 2022 and December 31, 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at Reporting Date Using
	March 31,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2022		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	20,851	$	20,851	$	—	$	—
Commercial paper		88,100		—		88,100		—
Corporate debt securities		3,617		—		3,617		—
U.S. government agency securities and treasuries		7,950		7,950		—		—
Total	$	120,518	$	28,801	$	91,717	$	—

	Fair Value Measurements at Reporting Date Using
	December 31,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2021		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	16,437	$	16,437	$	—	$	—
Commercial paper		106,277		—		106,277		—
Corporate debt securities		5,873		—		5,873		—
U.S. government agency securities and treasuries		8,041		8,041		—		—
Total	$	136,628	$	24,478	$	112,150	$	—

Available-for-Sale Investments (Tables)

3 Months Ended

Mar. 31, 2022

Investments Debt And Equity Securities [Abstract]

Summary of Available-for-Sale Securities Held

The following tables summarize the available-for-sale securities held at March 31, 2022 and December 31, 2021 (in thousands):

March 31, 2022	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	88,342	$	—	$	(242	)	$	88,100
Corporate debt securities		3,620		—		(3	)		3,617
U.S. government agency securities and treasuries		8,050		—		(100	)		7,950
Total	$	100,012	$	—	$	(345	)	$	99,667

December 31, 2021	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	106,298	$	8	$	(29	)	$	106,277
Corporate debt securities		5,876		—		(3	)		5,873
U.S. government agency securities and treasuries		8,062		—		(21	)		8,041
Total	$	120,236	$	8	$	(53	)	$	120,191

Property and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2022

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

	March 31,			December 31,
	2022			2021
Laboratory equipment	$	8,600		$	8,274
Computer and office equipment		795			756
Furniture and fixtures		500			500
Leasehold improvements		9,566			9,561
Construction in progress		848			623
		20,309			19,714
Less accumulated depreciation		(11,227	)		(10,626	)
Property and equipment, net	$	9,082		$	9,088

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2022

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31,		December 31,
	2022		2021
Payroll related	$	1,546	$	3,495
Professional fees		398		298
Research and development		450		336
Other		274		273
Total accrued expenses	$	2,668	$	4,402

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2022

Equity [Abstract]

Schedule of Shares of Common Stock Reserved for Future Issuance

	March 31, 2022
Common stock issuable under pre-funded warrants		2,548,117
Options exercisable to purchase common stock		2,279,425
Employee Stock Purchase Plan		—
Total		4,827,542

Equity-based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Equity-based Compensation Expenses

	Three Months Ended March 31,
	2022		2021
Research and development	$	375	$	415
General and administrative		515		462
	$	890	$	877

Schedule of Equity-based Compensation Expenses by Award Type

The following table summarizes equity‑based compensation expense by type of award for the three months ended March 31, 2022 and 2021 (in thousands):

	Three Months Ended March 31,
	2022		2021
Stock options	$	820	$	699
Restricted stock awards		53		172
Employee stock purchase plan		17		6
	$	890	$	877

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share

	As of March 31,
	2022		2021
Unvested restricted common stock awards		793,693		415,158
Outstanding options to purchase common stock		6,684,468		4,577,117
Potential shares issuable under the ESPP		—		—

Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cash, cash equivalents, and short-term marketable securities	$ 120,500
Restricted cash	1,097	$ 1,097
Accumulated deficit	$ 306,569	$ 290,872

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References + Details

Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	$ 120,518	$ 136,628
Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	20,851	16,437
Commercial Paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	88,100	106,277
U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	7,950	8,041
Corporate Debt Securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	3,617	5,873
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	28,801	24,478
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	20,851	16,437
Quoted Prices in Active Markets for Identical Assets (Level 1) \| U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	7,950	8,041
Significant Other Observable Inputs (Level 2)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	91,717	112,150
Significant Other Observable Inputs (Level 2) \| Commercial Paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	88,100	106,277
Significant Other Observable Inputs (Level 2) \| Corporate Debt Securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	3,617	5,873
Significant Unobservable Inputs (Level 3)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	0	0
Significant Unobservable Inputs (Level 3) \| Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Significant Unobservable Inputs (Level 3) \| Commercial Paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Significant Unobservable Inputs (Level 3) \| U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) \| Corporate Debt Securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	$ 0	$ 0

Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 100,012	$ 120,236
Gross unrealized gains		8
Gross unrealized losses	(345)	(53)
Fair Value	99,667	120,191
Commercial Paper
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	88,342	106,298
Gross unrealized gains		8
Gross unrealized losses	(242)	(29)
Fair Value	88,100	106,277
Corporate Debt Securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	3,620	5,876
Gross unrealized losses	(3)	(3)
Fair Value	3,617	5,873
U.S. Government Agency Securities and Treasuries
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	8,050	8,062
Gross unrealized losses	(100)	(21)
Fair Value	$ 7,950	$ 8,041

Available-for-Sale Investments - Additional Information (Detail) $ in Millions	Mar. 31, 2022 USD ($) Investment Security	Dec. 31, 2021 USD ($) Investment
Investments Debt And Equity Securities [Abstract]
Number of investments in unrealized loss position	28	20
Number of investments in unrealized loss position, more than twelve months	0	0
Aggregate fair value of securities in unrealized loss position \| $	$ 99.7	$ 72.2
Number of securities with other than temporary impairment \| Security	0

Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 20,309	$ 19,714
Less accumulated depreciation	(11,227)	(10,626)
Property and equipment, net	9,082	9,088
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	8,600	8,274
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	795	756
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	500	500
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,566	9,561
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 848	$ 623

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Payroll related	$ 1,546	$ 3,495
Professional fees	398	298
Research and development	450	336
Other	274	273
Total accrued expenses	$ 2,668	$ 4,402

Stockholders Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	Jul. 31, 2021	Jun. 30, 2019	Mar. 31, 2021	Sep. 30, 2021	Mar. 31, 2022
Common Stock
Class Of Stock [Line Items]
Sale of common stock, shares		6,340,771
Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		2,548,117
Warrants exercise price per share		$ 9.00
Warrants exercise price per share paid at closing of offering		8.99
Ginkgo Bioworks, Inc.
Class Of Stock [Line Items]
Sale of stock, price per share		$ 9.00
Proceeds from issuance of common stock and pre-funded warrants		$ 79.9
Ginkgo Bioworks, Inc. \| Common Stock
Class Of Stock [Line Items]
Sale of common stock, shares		6,340,771
Ginkgo Bioworks, Inc. \| Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		2,548,117
Warrants exercise price per share		$ 9.00
Warrants exercise price per share paid at closing of offering		$ 8.99
Warrants exercised					0
Cowen and Company, LLC \| ATM
Class Of Stock [Line Items]
Sale of common stock, shares			2,447,211	0
Proceeds from issuance of common stock, net of issuance costs			$ 8.1
Jefferies, LLC \| ATM
Class Of Stock [Line Items]
Sale of common stock, shares	0
Proceeds from issuance of common stock, net of issuance costs	$ 50.0

Stockholders Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)	Mar. 31, 2022 shares
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	4,827,542
Options Exercisable to Purchase Common Stock
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	2,279,425
Common Stock Issuable Under Pre-Funded Warrants
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	2,548,117

Equity-based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Jan. 01, 2022	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options granted		2,342,899
Weighted average exercise price		$ 1.99
Employee unrecognized compensation expense		$ 7.5
Employee unrecognized compensation cost, period of recognition		2 years 10 months 24 days
Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee unrecognized compensation expense		$ 1.6
Employee unrecognized compensation cost, period of recognition		3 years 6 months
Number of restricted stock awards granted		507,260
Weighted average grant date fair value		$ 1.97
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares available for issuance (in shares)	696,988
Shares available for future grants		1,341,301
Plan 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares available for issuance (in shares)	3,484,942
2017 Plan and 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants		2,461,519

Equity-based Compensation - Schedule of Equity-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 890	$ 877
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	375	415
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 515	$ 462

Equity-based Compensation - Schedule of Equity-based Compensation Expenses by Award Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 890	$ 877
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	820	699
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	53	172
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 17	$ 6

Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognition of revenue		$ 244
Current deferred revenue		314	$ 531
Ginkgo Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Prepayment to related party for collaboration agreement	$ 30,000
Related party transaction collaboration agreement, initial term	5 years
Current pre-paid research and development		900
Non-current pre-paid research and development		9,800
Roche Collaboration and Option Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognition of revenue		200
Roche Collaboration and Option Agreement \| Current Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Current deferred revenue		$ 300

Net Loss per Share - Additional Information (Detail)	1 Months Ended
Net Loss per Share - Additional Information (Detail)	Jun. 30, 2019 $ / shares shares
Common Stock $0.001 Par Value
Number of shares sold \| shares	6,340,771
Pre-Funded Warrants
Warrants to purchase shares of common stock \| shares	2,548,117
Warrants exercise price per share \| $ / shares	$ 9.00
Warrants exercise price per share paid at closing of offering \| $ / shares	$ 8.99

Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Unvested Restricted Common Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	793,693	415,158
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	6,684,468	4,577,117

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Jan. 21, 2022	Dec. 31, 2021
Gain Contingencies [Line Items]
Right of use asset - operating lease	$ 14,893,000		$ 13,889,000
Azzur
Gain Contingencies [Line Items]
Agreed to pay to renovate and upgrade cleanroom space		$ 650,000
Estimated project cost for access personal support and other services	3,100,000
Right of use asset - operating lease	$ 1,800,000

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Common stock, outstanding		70,267,586	69,698,844
Ginkgo Bioworks, Inc.
Related Party Transaction [Line Items]
Common stock, outstanding		6,340,771
Prepayment to related party for collaboration agreement	$ 30.0
Related party transaction collaboration agreement, initial term	5 years
Current Pre-Paid Research and Development		$ 0.9
Non Current Pre-Paid Research and Development		9.8
Prepaid research and development expenses		$ 0.5